This 2022 randomized, double-blind, placebo-controlled trial evaluated the safety and tolerability of nicotinamide riboside (NR) in 30 patients with clinically stable heart failure with reduced ejection fraction (HFrEF). Participants received escalating doses of NR, reaching 1,000 mg twice daily over 12 weeks. The study found that NR was safe and
This review highlights the pivotal role of NAD⁺ in cardiac and skeletal muscle health, emphasizing its antioxidant and anti-aging properties. Replenishment of NAD⁺ has been shown to ameliorate muscle dystrophy in mice by enhancing mitochondrial function and extending lifespan. Additionally, NAD⁺ supplementation improves cardiac relaxation in heart failure models by
This study explores the potential therapeutic benefits of growth hormone-releasing hormone (GHRH) receptor agonists for cardiac stem cells (CSCs) in heart failure treatment. GHRH-R agonists like JI-38, MR-356, and MR-409 were shown to stimulate CSC proliferation and survival, particularly under oxidative stress, by activating key cell signaling pathways (ERK and
This position paper from the International Lipid Expert Panel (ILEP), published in Nutrition Research Reviews (PMID: 32172721), evaluates the clinical evidence supporting the use of nutraceuticals in managing heart failure (HF). It highlights supplements such as coenzyme Q10, L-carnitine, omega-3 fatty acids, probiotics, beet nitrates, D-ribose, carnosine, hawthorn, and vitamin
This review article explores the cardiotonic herb Crataegus oxyacantha (hawthorn), highlighting its pharmacological and phytochemical properties that support cardiovascular health. It discusses how the plant’s active constituents—such as oligomeric procyanidins and flavonoids—contribute to improved coronary blood flow, exercise tolerance, and modulation of cardiac function through positive inotropic and negative chronotropic
This review explores the cardiovascular benefits of resveratrol (RES), detailing its molecular mechanisms, including its effects on cell longevity, energy metabolism in heart cells, and cardiac remodeling. RES’s anti-inflammatory and antioxidant properties improve endothelial function, reduce oxidative stress, and potentially offer therapeutic benefits in cardiovascular diseases, including COVID-19-related cardiovascular complications.
This observational study examined the effectiveness of beta-blockers in patients with stable coronary heart disease (CHD), suggesting that their routine use in all stable CHD patients may not be necessary. While beta-blockers significantly reduce mortality and recurrent cardiovascular events in patients with recent myocardial infarction or heart failure, their benefits
The review article examines the role of Coenzyme Q10 (CoQ10) in the management of chronic heart failure (HF), emphasizing its biochemical function in mitochondrial energy production and antioxidant activity. The Q-SYMBIO trial demonstrated that CoQ10 supplementation significantly reduced cardiovascular mortality by 42% (p=0.026) and all-cause mortality by 43% (p=0.036) over
This systematic review analyzed 14 studies involving 1,067 predominantly older adult males and evaluated the effectiveness of Coenzyme Q10 (CoQ10) as adjunctive therapy in patients with cardiovascular disease (CVD) and hypertension. Findings indicated that CoQ10 supplementation improved functional capacity in heart failure patients, increased serum CoQ10 levels, reduced major cardiovascular
Photobiomodulation (PBM) using light-emitting diodes (LEDs) was found to improve cardiac function in a mouse model of heart failure by enhancing ATP production and mitochondrial function while reducing myocardial fibrosis. The study, published in Frontiers in Cardiovascular Medicine (2021), suggests that PBM may serve as a non-invasive therapeutic approach for
